Verseau Therapeutics Appoints Karen Tubridy as Chief Development Officer
BEDFORD Mass. – September 7, 2021 – Verseau Therapeutics, Inc. today announced the appointment of
Karen Tubridy, Pharm.D. as Chief Development Officer. Karen brings over 25 years of drug development
experience within the biopharmaceutical industry. As CDO, Karen will play a leadership role in
advancing Verseau’s pipeline of first-in-class monoclonal antibodies that are directed at repolarizing
macrophages to enable the immune system to mount a potent attack on cancer.
“Karen has decades of experience advancing therapeutic programs into the clinic and through to
commercialization,” said John Edwards, Chief Executive Officer of Verseau Therapeutics. “Her product
development leadership will be instrumental in guiding Verseau as we prepare to become a clinical stage
company with the anticipated first-in-human dosing of our lead program, VTX-0811, over the coming
“Verseau’s macrophage repolarizing programs are being developed to be clinically relevant across a
broader patient population and with a more potent antitumor response than currently available
immunology-based therapies,” said Karen. “I look forward to joining the team at this pivotal time to help
guide the development of this new class of oncology therapeutics.”
Karen previously served as Senior Vice President, Global Programs and Chief Development Officer at
Akebia Therapeutics, where she was responsible for driving program strategy with operational
responsibilities for its lead clinical asset through NDA and J-NDA. Prior to joining Akebia, Karen was
Chief Development Officer at Eleven Biotherapeutics, where she led clinical, regulatory, quality, program
management and development strategy. She previously served as Senior Vice President, Clinical
Development and Medical Affairs at Inspiration Biopharmaceuticals. Before this, she held senior
positions in clinical and regulatory operations at Taligen Therapeutics and stayed on following the
company’s acquisition by Alexion Pharmaceuticals. Karen also served as Vice President, Clinical
Operations at Syntonix Pharmaceuticals and Biogen Idec Hemophilia. Karen holds a B.S. in pharmacy
and a Pharm.D. from the Massachusetts College of Pharmacy and Allied Health Sciences.
Verseau Therapeutics is advancing a new class of cancer immunotherapies to stimulate the conversion of
immuno-suppressive, pro-tumorigenic macrophages into pro-inflammatory macrophages. This
transformation, called macrophage repolarization, induces a coordinated immune response to fight cancer.
Preclinically this approach has been found to offer both a broader and more potent antitumor approach
than with currently available T cell-based immunotherapies. Verseau’s macrophage repolarization target
discovery engine leverages human and disease biology, as well as computational approaches in a patient-
focused discovery process. This led to the discovery and validation over 20 novel macrophage targets.
Verseau’s first-in-class monoclonal antibody candidates, VTX-0811 targeting PSGL-1 and VTX-1218
targeting VSIG4, are progressing toward clinical trials. https://www.verseautx.com/